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ABSTRACT
Background: Injectable methylxanthines are useful drugs in the treatment of asthma. The Asthma Prevention
and Management Guidelines (JGL) that are followed in Japan recommend the use of sustained-release theo-
phylline to control the disease and use of injectable methylxanthines to alleviate symptoms. In contrast, the
guidelines followed in the west do not promote theophylline use due to safety concerns, and the use of in-
jectable methylxanthines in particular are not recommended. We thus conducted a study on adult patients with
bronchial asthma or chronic obstructive pulmonary disease treated with theophylline and injectable methylxan-
thines in Japan in order to assess the safety of these drugs.
Methods: 876 patients were surveyed at 55 medical institutions by the Committee on the Safety of Sustained-
Release Theophylline and Injectable Methylxanthines (CST) of the Committee for Asthma Prevention and Man-
agement Guidelines of the Japanese Society of Allergology (JSA). 682 of the patients were evaluated for
safety.
Results: Adverse reactions including facial flushing, palpitations, headache, tinnitus, diaphoresis, nausea,
vomiting and tachycardia were reported by only 2 (0.29%) of the 682 patients, but none of these were serious.
Conclusions: The results confirm that injectable methylxanthines are safe, when used in accordance with the
JGL.
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INTRODUCTION
Injectable methylxanthines have been used in the
treatment of asthma. Herrmann1 administered amino-
phylline, an ethylenediamine salt of theophylline and
a methylxanthine, intravenously to patients with clus-
tering asthmatic attacks, and reported on the clinical
efficacy in 1937. Aminophylline injection (Neophyl-
linⓇ) was first marketed in Japan in 1950, and it is
now widely used as a therapeutic drug for bronchial
asthma. Aminophylline is a recommended first choice
drug for acute attacks in patients with moderate or
serious symptoms when inhalation of β2-agonist is
not effective according to the Asthma Prevention and
Management Guidelines (JGL). 2
The attitude toward theophylline, another methylx-
anthine, as a therapeutic drug as set down in the
therapeutic guidelines for asthma in the US, Canada,
UK and other European countries differs from that in
Japan, and its use is considerably limited in these
countries. The reason for this seems to be due to the
fact that the therapeutically effective margin of theo-
phylline is narrow and despite evidence of its efficacy,
there is concern about onset of serious adverse reac-
tions likely to be caused by elevation of blood concen-
tration above the practical range.
More than 10 million ampules of injectable amino-
phylline are prescribed annually in Japan, and no ma-
jor problems have been found clinically other than
health hazards due to overdose. Yet, while postmar-
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Table 1 ICH Definition of the Seriousness of Adverse Re-
actions＊
Serious: 
1. Results in death or injury
2. Is life-threatening or may result in injury
3. Requires hospitalization or prolongation of existing hospi-
talization
4. Results in congenital disease or abnormality in the next 
generation
5. Other events that may require intervention to prevent one 
of the outcomes listed in definitions 1―4
Moderate: Neither severe nor mild
Mild: When symptoms are judged by the atending physician 
to be mild and recovery is rapid.
(＊ICH: International Conference of Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use)
keting safety surveillance of new drugs is now man-
datory in Japan , aminophylline injection being an
older drug that was first marketed in 1950 has no
postmarketing safety data. Therefore, the CST in the
JSA decided to conduct a safety study on aminophyl-
line and theophylline (TheodripⓇ) injections in adults
to acquire such data.
This study was performed to determine the onset
of adverse reactions, particularly serious adverse re-
actions caused by aminophylline and theophylline .
The study targeted adult patients ranging in age from
15 to 64 years of age with bronchial asthma or
chronic obstructive pulmonary disease (COPD) in Ja-
pan and was conducted by physicians certified by the
JSA.
METHODS
SURVEY DESIGN
This survey was conducted in 55 institutions to which
JAS-certified physicians were affiliated . The target
symptom was dyspnea in patients with bronchial
asthma or COPD. The age of patients was restricted
to 15 years of age or more but less than 65 years of
age. The duration of the survey was set at 1 month
within the period from September 1 through Decem-
ber 31, 2001 as pre-designated by each participating
institution. All patients that received the injectable
methylxanthines were monitored for adverse reac-
tions during the observation period. The target ad-
verse reactions were those that occur during intrave-
nous infusion or within 6 hours after a bolus admini-
stration. The doses of the injectable methylxanthines
are the doses that are expected to be effective against
acute attacks in daily therapy.
SURVEY ITEMS
The following items were recorded in the survey :
gender, age, reason for use, component name, ad-
ministration date, daily dose, mode of administration,
concomitant use of other drugs and the presence of
adverse reactions . If an adverse reaction was ob-
served, the type of adverse reaction, date and time of
onset after the start of administration, seriousness,
and blood theophylline concentration were recorded.
The seriousness of adverse reactions was evalu-
ated according to the following criteria in accordance
with the ICH guidelines (Table 1).
RESULTS
NUMBER OF PARTICIPATING PATIENTS
The institutions which participated in this survey are
shown in Table 2. Injectable methylxanthines were
administered to 876 patients in 55 institutions during
the observation period, and completed questionnaires
were collected from these patients. A total of 194 pa-
tients were excluded from the evaluations due to vio-
lations of the inclusion or exclusion criteria. Specifi-
cally , 124 patients fell outside the designated age
group, 39 had answered the questionnaire twice, 12
received the drugs at times that were outside the des-
ignated observation period, 9 either had conditions or
diseases other than the targeted one or had received
different drugs, and 10 whose age or presence of ad-
verse reactions were not recorded. The recorded data
from 682 patients was ultimately used in the evalu-
ation of safety.
PATIENT BACKGROUNDS
The backgrounds of the 682 patients whose data
were used to evaluate the safety of the drugs are
shown in Table 3. The patients consisted of 294 males
(43.1%) and 388 females (56.9%). The reasons for use
were bronchial asthma in 673 patients (98.7%) and
COPD in 9 patients (1.3%). The drugs were used for
the treatment of dyspnea due to bronchial asthma in
most patients. The mode of administration was intra-
venous infusion in all patients, and aminophylline was
administered to 610 patients (89.4%) and theophylline
to 77 (11.3%). The dose of aminophylline most fre-
quently employed was 250 mg to 264 patients and 125
mg to 250 patients while theophylline was adminis-
tered at a dose of 200 mg to 68 patients. Concomitant
use of other drugs was recorded in 653 patients
(95.7%) with steroids used by 618 patients (94.6%), β-
agonists by 488 (74.7%) and oral methylxanthines by
357 (57.4%).
ONSET OF ADVERSE REACTIONS
None of the 682 patients evaluated for safety experi-
enced serious adverse reactions, and only 2 patients
(0.29%) had non-serious (mild or moderate) adverse
reactions. The details of the onset of adverse reac-
tions in these 2 patients are described below. Since
adverse reactions were observed in only 2 patients, a
stratified analysis by patient background was not car-
ried out. There are many patients who use oral theo-
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Table 2 Institutions that Participated in the Survey (in alphabetical order)
Nihon University Itabashi HospitalAsahi Chuo Hospital
Okayama Red Cross General HospitalChiba University
Osaka City University Medical SchoolChukyo Hospital
Rosai Hospital for SilicosisDoai Memorial Hospital
Saitama Medical SchoolDokkyo University School of Medicine
Sendai National HospitalEhime Prefectural Central Hospital
Sendai Open HospitalFujita Health University School of Medicine
Shimonita Kosei HospitalFukushima Medical University
Shizuoka Red Cross HospitalHitachi Totsuka General Hospital
Showa General HospitalInternational Medical Center of Japan
Showa University Fujigaoka HospitalIshikawa Prefectural Central Hospital
Showa University School of MedicineIwate Medical University
Teikyo University School of MedicineJapanese Red Cross Medical Center
Toho University School of Medicine, Sakura HospitalJobu Hospital for Respiratory Disease
Tohoku Rosai HospitalKameda General Hospital
Tohoku University School of MedicineKariya General Hospital
Tokyo Kyosai HospitalKihara Hospital
Tokyo Medical and Dental UniversityKinki University School of Medicine
Tokyo Metropolitan Hiroo General HospitalKurume University
Tone Chuo HospitalMaebashi-Kita Hospital
Tosei General HospitalMazda Hospital
Toyoko Hospital, St. Marianna University School of MedicineMeitetsu Hospital
Toyota Memorial HospitalNagoya Ekisaikai Hospital
Yokohama City Seibu Hospital, St. Marianna University 
School of Medicine
Nara Hospital Kinki University School of Medicine
National Fukuoka-Higashi Hospital
Yokohama City University School of MedicineNational Okayama Medical Center
Yugawara Kosei-Nenkin HospitalNational Sagamihara Hospital
Yukawa Naika ClinicNational Sanatorium Minami Okayama Hospital
phylline before administering aminophylline , there-
fore if theophylline is given for the first time, there is
a low possibility of the onset of adverse reactions
such as digestive symptoms which readily occur.
No serious adverse reactions were reported in the
194 patients that were excluded from the evaluation
of safety. One patient, a 71-year-old woman, did show
slight trembling of both knees.
PATIENT 1
The patient was a 57-year-old female . She received
250 mg of aminophylline diluted in 500 ml of diluent
solution by intravenous infusion over 2 hours as treat-
ment for acute aggravation of bronchial asthma. A β-
agonist ( skin patch ) , a steroid ( inhalation ) and
sustained-release theophylline ( 300 mgday ) were
used concomitantly as part of the long term manage-
ment. At 2 hours after the start of aminophylline infu-
sion, facial flushing, palpitations, headache, tinnitus
and diaphoresis developed; but all of the symptoms
were mild. Blood theophylline concentration at the
time of onset of these adverse reactions was not
measured. The patient did have a past history of facial
flushing and palpitations with aminophyline. The at-
tending physician commented that the adverse reac-
tions occurred due to acceleration of the infusion rate
by the patient herself.
PATIENT 2
The patient was a 21-year-old male . He presented
with acute aggravation of bronchial asthma at a
nearby hospital, and was treated with a total dose of
about 1000 mg of aminophylline . He subsequently
visited an institution participating in this survey be-
cause there was no improvement in the symptoms. At
the time of this visit, he was vomiting. A 125 mg dose
of aminophylline was additionally infused on that day,
and aminophylline was administered at a dose of 500
mgday from the next day for a total of 6 days. A β-
agonist (inhalation), a steroid (intravenous injection)
and epinephrine were used concomitantly to relieve
the patient from asthma exacerbations. The patient
had palpitations, nausea, vomiting and tachycardia at
2 hours after the start of aminophylline infusion on
the first day of administration. However, all the symp-
toms were moderate, and blood theophylline concen-
tration at the time of onset of the adverse reactions
was 19.5 μgml.
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Table 3 Background of Patients Evaluated for Safety (682 patients)
Number of patients ItemNumber of patients Item
(4.3%)29Not usedConcomitant
drugs
(43.1%)294Male
Sex
(95.7%)653Used(56.9%)388Female
(74.7%)488β-Agonist(3.4%)＜2315 ＜＿
Age (years)
20
(54.7%)357Inhalation(15.4%)＜10520 ＜＿ 
30
(0.8%)5Intravenous injection(17.4%)＜11930 ＜＿ 
40
(18.8%)123Patch application(19.9%)＜13640 ＜＿ 
50
(20.7%)135Oral(27.6%)＜18850 ＜＿ 
(94.6%)618Steroid60
(16.3%)＜11160 ＜＿ 
(46.2%)302Inhalation65
(68.9%)450Intravenous injection(98.7%)673
Bronchial 
asthma
Name of
disease
(reason for use) (23.0%)150Oral(1.3%)9COPD
(2.5%)16Epinephrine(100.0%)682InfusionMode of 
administration (11.9%)78Antibacterial drug(0.0%)0Bolus
(6.3%)41Macrolide(89.4%)610Aminophyline
Dose (mg/day)
(1.5%)10New quinolone(36.7%)250125
(4.4%)29Others(8.8%)60200
(57.4%)375Other methylxanthines(38.7%)264250
(56.0%)366Oral(5.3%)36300＜＿ 
(0.0%)0Suppository(11.3%)77Theophyline
(1.4%)9Not described(0.3%)2＜200
(10.0%)68200
(1.0%)7250＜＿ 
Note) Rates by type of concomitant drug are the ratios to the number of patients using concomitant drugs (653 patients).
DISCUSSION
To date there are no available reports on clinical stud-
ies conducted to examine the safety of injectable
methylxanthines, however, the following adverse re-
actions have been reported in the literature where
their efficacy was compared with a control group .
Carlos et al. compared an aminophylline 5.6 mgkg
group , a matching placebo group and a
hydrocortisone-salbutamol combination group , and
reported that the incidence of nausea and headache
in the aminophylline group was higher than that in
the other groups.3 Wrenn et al. looked at an amino-
phylline 5.6 mgkg group, a matching placebo group,
and a methylprednisolone-metaproterenol combina-
tion group, and reported a high frequency of nausea
in the aminophylline group.4 Carrier et al. compared
an aminophylline group with an oral theophylline-
epinephrine combination group, and reported a high
frequency of headache, nausea, vomiting and tachy-
cardia in the aminophylline group.5 Siegel et al. com-
pared an aminophylline (5.6 mgkg)-metaproterenol
combination group with a metaproterenol monother-
apy group, and reported high rates of nausea, vomit-
ing, anxiety , tremor and palpitations in the amino-
phylline combination group.6
From the experience with theophylline and in-
jectable methylxanthines in Japan to date, based on
anecdotal evidence, it seems that serious adverse re-
actions rarely occur, particularly in adults. However,
there is no scientific evidence based on strict surveys
to support this contention.
In the present survey, adverse reactions were re-
ported by 2 (0.29%) of the 682 patients evaluated for
safety, but none of them were serious. As previously
mentioned, the adverse reactions were facial flush-
ing, palpitations, headache, tinnitus and diaphoresis
in Patient 1, and palpitations, nausea, vomiting and
tachycardia in Patient 2. All of these symptoms are
adverse reactions that are associated with injectable
methylxanthines, and the present results agreed well
with the aforementioned results obtained from other
studies conducted in other countries. The adverse re-
actions that were observed in Patient 1 occurred pre-
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sumably due to acceleration of the infusion rate by
the patient herself during the administration. Patient
2 had been treated with a total of approximately 1000
mg of aminophylline prior to hospitalization at the
participating institution , and the adverse reactions
that were observed could have been due to an over-
dose, which was supported by a blood concentration
of theophylline 19.5 μgml.
JGL describes the use of injectable aminophylline
as follows : “For the treatment of attacks showing
moderate symptoms, continuous mild symptoms or
more serious symptoms , dilute about 6 mgkg of
aminophylline with 200 to 250 ml of an isotonic solu-
tion for infusion, and infuse half in 15 minutes and the
remaining half in 45 minutes. If toxic symptoms such
as headache, nausea, vomiting, tachycardia and ar-
rhythmia occur during infusion, immediately discon-
tinue administration. Blood theophylline concentra-
tion should be monitored during treatment . This
aminophylline dose has been chosen based on the
premise that a sufficient amount of theophylline was
not administered before the onset of the attack, and
the theophylline clearance is normal . When more
than 600 mgday of theophylline has been adminis-
tered, or when the blood theophylline concentration
is 8 μgml or higher, reduce the dose of aminophyl-
line to half. Do not administer aminophylline alone
but in combination with a steroid and epinephrine.”
In the present survey, the most frequently adminis-
tered dose was 250 mg of aminophylline as recom-
mended by the JGL, followed by a dose of 125 mg. It
was inferred that the dose of aminophylline was de-
creased to 125 mg because an oral xanthine drug had
been used in 56.0% of the patients. The mode of ad-
ministration was intravenous infusion for all the pa-
tients . Theophylline was administered at a dose of
200 mg in almost all of the patients since only the 200
mg dose of theophylline injection is available.
We found that the frequency of adverse reactions
caused by injectable methylxanthines was very low,
as demonstrated by the results described above, and
no serious adverse reactions were reported. There-
fore, these data may suggest that injectable methylx-
anthines are highly safe drugs when used appropri-
ately. It should be noted that this survey was con-
ducted at medical institutions staffed by JSA-certified
physicians who fully understand the JGL and package
inserts, and their participation may have greatly con-
tributed to the favorable results. However, the results
seem to confirm that injectable methylxanthines are
safe, when used in accordance with JGL and instruc-
tions provided in package inserts which would be
true when used even by physicians who are not JSA-
certified.
The price of the aminophylline injection is ¥94 to
¥97 (about $0.9) per ampule and that of the theophyl-
line injection is ¥269 (about $2.5) per bag as of Au-
gust 1, 2003. These drugs are less expensive than
other available drugs for the treatment of asthma, and
therefore, we can recommend their use for the treat-
ment of bronchial asthma or COPD from the stand-
point of medical costs.
Injectable methylxanthines are safe drugs when
used in accordance with the JGL and instructions pro-
vided in package inserts.
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